4basebio PLCLSE: 4BB

4basebio PLC - Half-year Report for the six months ended 30 June 2026

Sep 29, 2026 at 8:16 AM EDT · Issued by 4basebio PLC

Summary by 6ix AI

4basebio PLC, a UK maker of synthetic DNA for genomic medicines and advanced therapies, reported unaudited results for the six months ended June 30, 2026 (H1 2026). Revenue fell to GBP0.3 million from GBP1.2 million in the same period of 2025 (H1 2025), after project delays, and the loss was GBP8.9 million (H1 2025 loss: GBP7.8 million).

Key details

The company attributes the lower revenue to project delays from general market headwinds and to the prior-year period, when revenue came from a single large clinical pharma contract. It attributes the loss to investments in technology, manufacturing and commercial capability and to project revenues deferred into H2 2026 and 2027.
Sales orders for H1 2026 were GBP1.2 million, a 210% increase compared to H1 2025 sales orders of GBP0.4 million. The company says its qualified new business pipeline (potential new business it has assessed) is GBP63 million, up six-fold since the third quarter of 2025.
Cash was GBP14.1 million at June 30, 2026 (December 31, 2025: GBP17.8 million) following a EUR7 million drawdown under the 2Invest AG loan facility; the company says this gives it cash into late 2027. Net cash outflow from operating activities was GBP8.4 million (H1 2025: GBP8.2 million).
4basebio extended its existing relationship with a Tier 1 pharmaceutical customer to include a new modality (type of therapy), supporting the customer's Phase 1 (early-stage) cell therapy programme.
The company also secured a clinical supply agreement supporting a Phase 2 clinical trial, signed a collaboration and marketing agreement with Genezen, a viral vector contract manufacturer, and launched a single-stranded DNA platform.

What’s still pending

The company says sales orders of GBP1.4 million executed to the date of its report give visibility over revenue of GBP1.2 million to be recognised over the following 12 months.
The company expects HQ and GMP (good manufacturing practice) orders in late-stage contracting, along with multiple well-progressed HQ and GMP opportunities, to increase revenue recognition in H2 2026 and 2027.
The company expects net cash outflows from operations to reduce in H2 2026 and into 2027.

6ix AI wrote this summary from the release below and checked it against the release.

On 6ix: 6ix.com/news/4basebio-plc-half-year-report-for-the-six-months-ended-30-june-2026

Watch 4basebio's latest call4basebio (LSE:4BB) — Investor Presentation · Replay · Jun 29 Read the transcript of 4basebio (LSE:4BB) — Investor Presentation

Cambridge, UK - 4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing for next-generation genomic medicines and advanced therapies, announces its unaudited half-year results for the six months ended 30 June 2026 ('H1 2026').

Operational and Commercial Highlights (including post period end)

New leadership team driving the Group's next phase of growth

Qualified new business pipeline of GBP63 million, up six-fold since Q3 2025, reflecting strong momentum in the business and the impact of new commercial team; pipeline demonstrates substantial demand and underpins future growth in 2027 and beyond

Secured clinical supply agreement to support Phase 2 clinical trial reflects increased adoption of synthetic DNA for clinical stage assets

Signed a strategic collaboration and marketing agreement with Genezen, a best-in-class viral vector CDMO; 4basebio selected as partner for excellent quality, reliability and safety

Commercial launch of innovative new offerings including single-stranded DNA (ssDNA) platform, and expanded NDA offering to enable high capacity, fast turnaround time DNA for personalised cancer vaccines (PCV)

Announced today, extension of existing relationship with Tier 1 pharmaceutical customer to include new modality, supporting its Phase 1 cell therapy programme with HQ opNDA

Financial Highlights

Sales orders for H1 2026 of GBP1.2 million, a 210% increase compared to H1 2025 sales orders (GBP0.4 million)

Revenue for H1 2026 of GBP0.3 million (H1 2025: GBP1.2 million), reflecting project delays due to general market headwinds that are now starting to ease, and a strong prior year comparator where revenues were derived from a single large clinical pharma contract

Cash balances of GBP14.1 million at period end (31 December 2025: GBP17.8 million) following EUR7 million drawdown under the 2Invest AG loan facility, providing a cash runway into late 2027

Loss for the period of GBP8.9 million (H1 2025 loss: GBP7.8 million) reflecting strategic investments in technology, manufacturing and commercial capability and deferrals of project revenues into H2 2026 and 2027

Net cash outflow from operating activities of GBP8.4 million (H1 2025: GBP8.2 million)

Outlook

Substantial and growing pipeline coupled with sizeable market opportunity for synthetic DNA underpins the Group's expected future growth

Sales orders executed to the date of this report of GBP1.4 million (including previously announced Phase II clinical supply agreement and today's announced extended relationship with a Tier 1 pharma) provide visibility over revenue of GBP1.2 million to be recognised over the next 12 months

HQ and GMP orders in late-stage contracting along with multiple well-progressed HQ and GMP opportunities expected to significantly increase revenue recognition in H2 2026 and 2027

With significant anticipated revenue growth and expected reduction in operating expenses following a period of strategic investment, the Group expects net cash outflows from operations to reduce in H2 2026 and also into 2027

Commenting on the interim results, Dr Amy Walker, CEO, said 'Following our investment into operational and commercial infrastructure in 2025, H1 2026 was a period of strong commercial momentum which positions us well to deliver future growth. I strongly believe that our differentiated technology and strengthened commercial capability will allow us to benefit from the expected growth in advanced therapies. Our enhanced commercial capabilities and team are reflected by a six-fold growth in our qualified pipeline and we enter H2 2026 with greatly enhanced visibility over future revenues.

We continue to receive consistently excellent feedback on our technology from our diversified customer base spanning biotech, pharma and CDMO across multiple modalities, and are encouraged by the continued adoption of our technology for clinical stage assets following our MHRA GMP certification, including a Phase 2 clinical trial. The long-term outlook for the synthetic DNA market and 4basebio remains exciting as clients increasingly pivot to a safer, quicker and high performance DNA source. We look forward to driving further commercial momentum with partners and clients through the remainder of 2026 and into 2027.'

Contact:

Dr. Amy Walker

Tel: +44 (0)12 2396 7943

Jo Turner

Tel: +44 (0)20 7213 0880

Jessica Hodgson

Tel: +44 (0)203 707 5700

4basebio PLC on 6ix